These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26926642)

  • 1. Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.
    Shields RK; Clancy CJ; Press EG; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3187-92. PubMed ID: 26926642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
    Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.
    Borer A; Saidel-Odes L; Riesenberg K; Eskira S; Peled N; Nativ R; Schlaeffer F; Sherf M
    Infect Control Hosp Epidemiol; 2009 Oct; 30(10):972-6. PubMed ID: 19712030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
    Cprek JB; Gallagher JC
    Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit.
    Vardakas KZ; Matthaiou DK; Falagas ME; Antypa E; Koteli A; Antoniadou E
    J Infect; 2015 Jun; 70(6):592-9. PubMed ID: 25447713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
    Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.
    Viale P; Giannella M; Lewis R; Trecarichi EM; Petrosillo N; Tumbarello M
    Expert Rev Anti Infect Ther; 2013 Oct; 11(10):1053-63. PubMed ID: 24073806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
    Brizendine KD; Richter SS; Cober ED; van Duin D
    Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.
    Oliva A; D'Abramo A; D'Agostino C; Iannetta M; Mascellino MT; Gallinelli C; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2014 Jun; 69(6):1718-20. PubMed ID: 24521856
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.
    Petrosillo N; Giannella M; Lewis R; Viale P
    Expert Rev Anti Infect Ther; 2013 Feb; 11(2):159-77. PubMed ID: 23409822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study.
    Jiao Y; Qin Y; Liu J; Li Q; Dong Y; Shang Y; Huang Y; Liu R
    Pathog Glob Health; 2015 Mar; 109(2):68-74. PubMed ID: 25707874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aspects of the antimicrobial resistence profile in infections with Escherichia coli and Klebsiella pneumoniae in diabetic patients].
    Petrovici CG; Dorobăţ C; Matei M; Teodor A; Luca V; Miftode E
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):769-75. PubMed ID: 22046785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.
    Ny P; Nieberg P; Wong-Beringer A
    Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections.
    Ben-David D; Kordevani R; Keller N; Tal I; Marzel A; Gal-Mor O; Maor Y; Rahav G
    Clin Microbiol Infect; 2012 Jan; 18(1):54-60. PubMed ID: 21722257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.